> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Determined for Entyce
- URL: https://www.fdaweb.com/regulatory-review-period-determined-for-entyce/
- Published: 2018-01-11T12:00:00.000Z
- Updated: 2026-09-14T23:12:42.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140482

*Federal Register* notice: FDA has determined that the regulatory review period for RaQualia Pharma’s Entyce (capromorelin), indicated for appetite stimulation in dogs, was 1,645 days. Of this time, 1,589 days occurred during the testing phase, while 56 days occurred during the approval phase. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-01-11/pdf/2018-00358.pdf?ref=fdaweb.com).